144 related articles for article (PubMed ID: 7493340)
1. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach.
Juhl H; Sievers M; Baltzer K; Helmig F; Wolf H; Brenner W; Kalthoff H
Cancer Res; 1995 Dec; 55(23 Suppl):5749s-5755s. PubMed ID: 7493340
[TBL] [Abstract][Full Text] [Related]
2. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
3. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
[TBL] [Abstract][Full Text] [Related]
4. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.
Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
Mol Immunol; 1990 Oct; 27(10):957-64. PubMed ID: 2233757
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
[TBL] [Abstract][Full Text] [Related]
6. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
[TBL] [Abstract][Full Text] [Related]
7. The selective cytotoxicity of cobra venom factor immunoconjugate on cultured human nasopharyngeal carcinoma cell line.
Wang XM; Huang SJ
Hum Exp Toxicol; 1999 Feb; 18(2):71-6. PubMed ID: 10100018
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha-2b immunoconjugate for improving immunoscintigraphy and immunotherapy.
Pallela VR; Rao SP; Thakur ML
J Nucl Med; 2000 Jun; 41(6):1108-13. PubMed ID: 10855643
[TBL] [Abstract][Full Text] [Related]
9. Antibody conjugates with cobra venom factor. Synthesis and biochemical characterization.
Petrella EC; Wilkie SD; Smith CA; Morgan AC; Vogel CW
J Immunol Methods; 1987 Nov; 104(1-2):159-72. PubMed ID: 3500233
[TBL] [Abstract][Full Text] [Related]
10. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation.
Zara J; Pomato N; McCabe RP; Bredehorst R; Vogel CW
Bioconjug Chem; 1995; 6(4):367-72. PubMed ID: 7578355
[TBL] [Abstract][Full Text] [Related]
11. Carbohydrate-directed conjugation of cobra venom factor to antibody by selective derivatization of the terminal galactose residues.
Fu Q; Gowda DC
Bioconjug Chem; 2001; 12(2):271-9. PubMed ID: 11312689
[TBL] [Abstract][Full Text] [Related]
12. Preparation of complement fragments C3b and C3a from purified rat complement component C3 by activated cobra venom factor.
Usami M; Ohno Y
J Pharmacol Toxicol Methods; 2005; 52(2):260-3. PubMed ID: 16125624
[TBL] [Abstract][Full Text] [Related]
13. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
14. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
15. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus.
Rehana S; Manjunatha Kini R
Toxicon; 2007 Jul; 50(1):32-52. PubMed ID: 17412383
[TBL] [Abstract][Full Text] [Related]
16. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
Eggertsen G; Lundwall A; Hellman U; Sjöquist J
J Immunol; 1983 Oct; 131(4):1920-3. PubMed ID: 6194220
[TBL] [Abstract][Full Text] [Related]
17. Complement dependence of antibody-induced mesangial cell injury in the rat.
Yamamoto T; Wilson CB
J Immunol; 1987 Jun; 138(11):3758-65. PubMed ID: 3495569
[TBL] [Abstract][Full Text] [Related]
18. Prolonged cardiac allograft survival in presensitized rats after a high activity Yunnan-cobra venom factor therapy.
Li R; Chen G; Guo H; Wang DW; Xie L; Wang SS; Wang WY; Xiong YL; Chen S
Transplant Proc; 2006 Dec; 38(10):3263-5. PubMed ID: 17175243
[TBL] [Abstract][Full Text] [Related]
19. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.
Vogel CW; Finnegan PW; Fritzinger DC
Mol Immunol; 2014 Oct; 61(2):191-203. PubMed ID: 25062833
[TBL] [Abstract][Full Text] [Related]
20. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
